WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 9 mai 2023 16:14

Laboratory Information

Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Equine Infectious Anemia
Address of laboratory:	678 Harping Road
Tel.:	+8645151051749
E-mail address:	wangxiaojun@caas.cn
Website:	www.hvri.ac.cn
Name (including Title) of Head of Laboratory (Responsible Official):	Prof. Xiaojun Wang
Name (including Title and Position) of WOAH Reference Expert:	Prof. Xiaojun Wang
Which of the following defines your laboratory? Check all that apply:	Academic institution

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
cELISA	Yes	1788	0
AGID	Yes	58	0
Colloidal gold strip test	No	1015	0
Direct diagnostic tests		Nationally	Internationally
real time PCR	Yes	29	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAH MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Equine infectious Anemia virus-antigen	AGID	Harbin National Engineering Research Center of Veterinary Biologics Corp.	1226ML	6ML	1	Asia and Pacific
Equine infectious Anemia -Positive Serum	AGID	Harbin National Engineering Research Center of Veterinary Biologics Corp.	2704ML	18ML	1	Asia and Pacific
Equine infectious Anemia -Positive Serum	cELISA	Harbin National Engineering Research Center of Veterinary Biologics Corp.	436ML	12ML	1	Asia and Pacific
Equine infectious Anemia -Negtive Serum	cELISA	Harbin National Engineering Research Center of Veterinary Biologics Corp.	436ML	12ML	1	Asia and Pacific

4. Did your laboratory produce vaccines?

Not applicable

5. Did your laboratory supply vaccines to WOAH Members?

Not applicable

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

Yes

NAME OF THE WOAH MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
JAPAN	For using of the AGID reagents	Remote
KAZAKHSTAN	Consulting on diagnostic method for EIA	Training courses were provided in China
HONG KONG	Technology exchange	Remote

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Development of a rapid test for the diagnosis of salmonella abortion in horses based on monoclonal antibodies	2021-2023	Development of a rapid test for salmonella abortion in horses	S.Seifullin Kazakh Agro Technical University	KYRGYZSTAN
Joint research on prevention and control of cross border animal diseases between China and Kazakhstan	2020-2023	To study epidemilogy and contro of equine infectious diseses	S.Seifullin Kazakh Agro Technical University	KAZAKHSTAN
Evaluation of updated AGID kit developed by our lab	2022	Compare Chinese updated AGID kit with other kits	Hiroshi Bannai, Equine Research Institute, Japan Racing Association	JAPAN
Development and evaluation of a blocking ELISA for the deteciton of antibodies against EIAV	2017-2023	The evaluation of a blocking ELISA	Ivancho Naletoski, International Atomic Energy Agency	AUSTRIA
Development and evaluation of a blocking ELISA for the deteciton of antibodies against EIAV	2017-2023	The evaluation of a blocking ELISA	Maria Barrandeguy, Instituto Nacional de Tecnología Agropecuaria (INTA)	ARGENTINA
Development and evaluation of a blocking ELISA for the deteciton of antibodies against EIAV	2017-2023	The evaluation of a blocking ELISA	Miño Samuel, Instituto Nacional de Tecnología Agropecuaria (INTA)	ARGENTINA
Development and				

evaluation of a blocking ELISA for the deteciton of antibodies against EIAV	2018-2023	The evaluation of a blocking ELISA	Patrick Imtung Lau,	HONG KONG
Development and evaluation of a blocking ELISA for the deteciton of antibodies against EIAV	2019-2023	The evaluation of a blocking ELISA	Ulrich Wernery, Central Veterinary Research Laboratory	UNITED ARAB EMIRATES
Development and evaluation of a blocking ELISA for the deteciton of antibodies against EIAV	2019-2023	The evaluation of a blocking ELISA	Rekha Raghavan, Central Veterinary Research Laboratory	UNITED ARAB EMIRATES

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:
Case report, disease outbreak bullutin

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:
Case report, disease outbreak bullutin

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

One article named "Development and evaluation of a blocking Enzyme Linked Immunosorbent Assay for universal serological diagnosis of Equine infectious anemia" was submitted to the journal of Applied Microbiology and Biotechnology.

b) International conferences:

2

1)"The First China Kazakhstan Veterinary Medicine Science and Technology Postgraduate Academic Forum", 8 May 2022 via Zoom, China and Kazakstan.

2)Training on Laboratory Techniques for Equine Diseases is performing for three researchers from S.Seifullin Kazakh Agro Technical University for three months, from December 2022 to February 2023, in our reference lab.

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

1
https://rr-asia.oie.int/en/
The OIE Regional Representation for the Asia Pacific

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

Yes

a) Technical visit : 0

b) Seminars : 2

c) Hands-on training courses: 0

d) Internships (>1 month) 1

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
B	The Republic of Kazakhstan	25
D	The Republic of Kazakhstan	3

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	jpg	CNAS EIA CHINA 20220124110915.jpg

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
AGID for testing EIAV antibodies	CNAS
HI test for testing EIV antibodies	CNAS

20. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

Implement China's Regulation on Biosafety Management of Pathgenic Microbiology Laboratory.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

No

24. Are you a member of a network of WOAH Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOAH REF. LABS/ ORGANISING WOAH REF. LAB.

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen?

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAH?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Review of WOAH Standards	Harbin	Annex-10-Chapter-12.2-Infection with Taylorella equigenitalis
Review of WOAH Standards	Harbin	Annex-11-Chapter-12.6-Equie influenza
Review of WOAH Standards	Harbin	Annex-12-Chapter-12.7-Equine piroplasmosis

29. Additional comments regarding your report:

Yes

International activities were largely impacted by the COVID-19 pandemic. The horse movement and activiteis were reduced as well.

The TOR3 Part could not be saved, I copy the information as the following:

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

Yes

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

If the answer is yes to at least one of the previous two questions, please provide information on where detailed information can be obtained (e.g. website, publication or postal address where the report may be requested)
Yes

NAME OF THE NEW TEST OR DIAGNOSTIC METHOD DEVELOPED DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)

cELISA for dection of antibody of EIAV Paper is currently under reviewing.

Colloidal gold strip test Paper is currently under preparation.

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

If the answer is yes to at least one of the previous two questions, please provide information on where the detailed information can be obtained (e.g. website, publication or postal address where the report may be requested)
No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?
No